Aptinyx’s Mid-Stage NMDA Receptor Fails to Hit Endpoints in Neuropathic Pain Study 0 16.01.2019 03:00 Feedity.com Shares of Illinois-based Aptinyx Inc. have plunged more than 67 percent in premarket trading after the company announced its mid-stage treatment for painful diabetic peripheral neuropathy failed to show statistical significance. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
